Pediatric asthma is chronic inflammation of the airways characterized by an obstruction of airflow. It is the most common chronic illness found in children and infants and is not easily detectable. The symptoms of pediatric asthma include a whistling sound while breathing, rapid & labored breathing, chest pain, coughing, and less energy or feeling of tiredness. A few children experience asthma when they perform any physical activity. This is known as exercise-induced bronchospasm. Pediatric asthma has no cure but is controllable through the right medications and treatment plan to further prevent lung damage. However, in some children, unmanaged asthma can lead to fatal asthma attacks. Risk factors that lead to the development of childhood asthma are allergies, low birth weight, family history of allergies or asthma, and others. As estimated by the World Health Organization (WHO), there were 383,000 deaths worldwide due to asthma. Currently, there are 235 million patients suffering from asthma globally. The causes of pediatric asthma are unknown, however an overly sensitive immune system could be a risk factor. A sensitive immune system leads to the swelling of lungs and airways, which further generate mucus when exposed to triggers owing to allergies of dust, pollen, air pollutants, viral infections, and physical activities. Pediatric asthma is incurable, however it can be prevented through regular monitoring, limiting smoking around children, controlling heartburn, and other factors. 

The global pediatric asthma treatment market is driven by an increase in the incidence of asthma, rise in allergy cases, availability of advanced inhaler devices and innovative biological drugs, and growing pollution levels. Also, increase in awareness about the diagnosis of asthma and improving health care facilities are likely to drive the market. Technological advancement is a major factor in the treatment of pediatric patients. Advanced monitoring devices manage pediatric asthma and help in controlling the condition. As estimated by the American Lung Association, the Centers for Disease Control and Prevention (CDC), and the National Institute of Allergy and Infectious Diseases (NIAID), 6 million children are affected by asthma currently. Approvals of new therapies are also a driving factor for the global pediatric asthma treatment market. However, patent expiry of drugs, increase in preference for generic drugs, and high cost of pediatric asthma treatment are estimated to restrain the global pediatric asthma treatment market. Increase in mergers and acquisitions, collaborations, and partnerships; rise in the popularity of combination therapies; and new product launches are estimated to offer investment opportunities to companies operating in the global pediatric asthma treatment market. 

The global pediatric asthma treatment market can be segmented based on product, route of administration, end-user, and region. Based on product, the global pediatric asthma treatment market can be bifurcated into drug class and inhaled medication devices. The drug class segment can be further divided into long-term control medications, quick-relief medications, and others. The long-term medication sub-segment can be further segmented into inhaled corticosteroids, leukotriene modifiers, combination inhalers, and theophylline. The quick relief medications sub-segment can be further categorized into short-acting beta agonists, ipratropium (Atrovent HFA), oral and intravenous corticosteroids, and immunomodulatory agents. The others sub-segment can be further divided allergy medications, omalizumab (Xolair), and allergy shots (immunotherapy). Inhaled devices consist of a measured dose of medicines. The inhaled devices segment can be further classified into pressurized metered dose inhalers, autohalers (dry powder inhalers), nebulizers, and accuhalers & turbuhalers. Metered dose inhalers are the most commonly used devices. In terms of route of administration, the global market can be categorized into oral route, nasal route, and parenteral route. Based on end-user, the global pediatric asthma treatment market can be classified into hospitals, clinics, home care, and others. 

In terms of region, the global pediatric asthma treatment market can be segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The pediatric asthma treatment market in North America is likely to be propelled by developed health care infrastructure, innovative drugs, technologically advanced asthma treatment, and increase in the number of asthma patients in the region. North America accounts for a dominant market share, followed by Europe and Asia Pacific. The market in Asia Pacific is expected to expand at at rapid rate, owing to a rise in the number of asthma patients, environmental changes, increase in disposable income, and developing health care infrastructure in the region. 

Major players operating in the global pediatric asthma treatment market are GlaxoSmithKline plc, Pfizer Inc., AstraZeneca, Boehringer Ingelheim International GmbH, OPKO Health, Medisol Lifescience Pvt. Ltd, Teva Pharmaceutical Industries Ltd., and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.